Delivery Order SPE2DB20D2104-SPE2DB23FR07A
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,918.53 firm fixed price delivery order is for the supply of 4567531714 Albuterol HFA 90 MCG Inhalers 8.5GM. The contract has an ultimate completion date of March 12, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) under a Delivery Order valued at $1,171.89. The contract is for the supply of Albuterol HFA 90 MCG Inhaler 8.5GM, a critical medical commodity used in respiratory care. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,094.60 firm-fixed-price delivery order is for the supply of 4566373808 ALBUTEROL HFA 90 MCG INHALER 8.5GM. The contract has a ceiling value of $1,094.60 and an ultimate completion date of November 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,193.56 Firm Fixed Price Delivery Order contract is for the supply of 4566873689 ALBUTEROL HFA 90 MCG INHALER 8.5GM. The contract has an ultimate completion date of January 9, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,461.04, is a Firm Fixed Price Delivery Order for the supply of 4567342018 - ALBUTEROL HFA 90 MCG INHALER 8.5GM. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,425.19, is for the delivery of 4563268448 - Albuterol HFA 90 mcg inhalers. It is a firm fixed-price delivery order with a completion date of January 9, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,986.30 firm fixed-price delivery order is for the supply of 4560842748 – ALBUTEROL HFA 90 MCG INHALER 8.5GM. The contract has an ultimate completion date of May 8, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,530.22, is for the delivery of Albuterol HFA 90 MCG inhalers. The contract is a Firm Fixed Price Delivery Order with a completion date of May 17, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of albuterol HFA 90 mcg inhalers. The $1,019.00 firm fixed-price contract has a completion date of July 2, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds significant Indefinite Delivery Contracts (IDCs) with the DLA and the Department of Justice Federal Bureau of Investigation, valued at $999,999,999 and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The $2,214.23 firm fixed-price contract is for the supply of 8.5 gram Albuterol HFA 90 MCG inhalers, with a performance period through September 9, 2024. Amerisourcebergen, one of the largest pharmaceutical distributors in the United States, has been awarded numerous federal contracts and indefinite delivery contracts (IDCs) from various defense...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FR07ADelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,605.96 delivery order is for the supply of Albuterol HFA 90 MCG inhalers, with an ultimate completion date of November 15, 2022. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This single-award IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 11/14/22 |